葛兰素史克(纽约证券交易所股票代码：GSK)减持Five Third Bancorp

Fifth Third Bancorp cut its holdings in GSK plc (NYSE:GSK – Get Rating) by 5.0% during the 1st quarter, Holdings Channel.com reports. The fund owned 21,055 shares of the pharmaceutical company's stock after selling 1,116 shares during the quarter. Fifth Third Bancorp's holdings in GSK were worth $917,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Tyler Stone Wealth Management bought a new stake in GSK in the fourth quarter worth about $26,000. Clearview Wealth Advisors LLC purchased a new position in GSK in the 4th quarter worth about $27,000. Allegheny Financial Group LTD purchased a new position in GSK in the 4th quarter worth about $27,000. Glassman Wealth Services increased its stake in GSK by 71.3% in the 4th quarter. Glassman Wealth Services now owns 627 shares of the pharmaceutical company's stock worth $28,000 after purchasing an additional 261 shares in the last quarter. Finally, Paragon Capital Management Ltd purchased a new position in GSK in the 4th quarter worth about $31,000. Hedge funds and other institutional investors own 32.76% of the company's stock.

Get

GSK

alerts:

A number of equities analysts recently weighed in on the company. JPMorgan Chase & Co. lifted their price target on GSK from GBX 1,740 ($21.07) to GBX 1,900 ($23.01) in a research note on Thursday, April 28th. StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a research note on Wednesday. Finally, Barclays lifted their price target on GSK from GBX 1,775 ($21.49) to GBX 1,800 ($21.80) in a research note on Friday, April 29th. Six analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $1,850.00.

Shares of NYSE GSK opened at $43.30 on Wednesday. The stock has a market cap of $110.06 billion, a price-to-earnings ratio of 15.63, a PEG ratio of 1.96 and a beta of 0.61. The business has a 50 day simple moving average of $43.58 and a 200 day simple moving average of $43.81. GSK plc has a 52 week low of $37.80 and a 52 week high of $46.97. The company has a debt-to-equity ratio of 1.29, a quick ratio of 0.95 and a current ratio of 1.19.

GSK (NYSE:GSK – Get Rating) last issued its quarterly earnings results on Wednesday, April 27th. The pharmaceutical company reported $0.88 EPS for the quarter, topping analysts' consensus estimates of $0.77 by $0.11. GSK had a return on equity of 28.13% and a net margin of 14.03%. The company had revenue of $13.12 billion during the quarter, compared to analyst estimates of $11.97 billion. On average, analysts predict that GSK plc will post 3.16 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, July 1st. Stockholders of record on Friday, May 20th were issued a dividend of $0.3496 per share. The ex-dividend date of this dividend was Thursday, May 19th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 3.23%. GSK's dividend payout ratio (DPR) is presently 48.38%.

GSK Profile (Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

See Also

• Get a free copy of the StockNews.com research report on GSK (GSK)
• 3 Home Improvement Stocks That Can Renovate Your Portfolio
• Get Defensive With These Three Upgrades
• Looking to Dump These 3 Possible Delisted Chinese Stocks? Let's Take a Look.
• Vera Bradley Stock Getting Cheap
• 3 Education Stocks to Enroll in This Summer

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK – Get Rating).

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.